Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Vilma Pacheco-Barcia

Citation

Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239

Authors

V.E. Pacheco-Barcia1, R. Mondejar2, T. France3, J. Asselah4, O. Donnay2, G. Zogopoulos5, N. Bouganim3, K. Guo3, E. Martin6, T. Alcindor7, R. Colomer Bosch2

Author affiliations

  • 1 Medical Oncology, Hospital Universitario de La Princesa. Instituto de Investigacion Sanitaria La Princesa, 28006 - Madrid/ES
  • 2 Medical Oncology, Hospital Universitario de La Princesa, 28006 - Madrid/ES
  • 3 Medical Oncology, McGill University Health Centre, H4A3J1 - Montreal/CA
  • 4 Oncology, McGill University Health Centre - Glen Site, H4A 3J1 - Montreal/CA
  • 5 Surgical Oncology, McGill University Health Centre, H4A3J1 - Montreal/CA
  • 6 Surgical Oncology, Hospital Universitario de La Princesa, 28006 - Madrid/ES
  • 7 Medical Oncology, McGill University Health Centre - Glen Site, H4A 3J1 - Montreal/CA
More

Resources

Abstract 3277

Background

Cancer-related inflammation is a distinctive feature of the development and progression of PC. However, the relationship between the systemic inflammatory response and survival has not been evaluated as a predictive factor of chemotherapy. The aim of this study was to evaluate the prognostic and predictive value of a baseline SIRI based on peripheral neutrophil, monocyte, and lymphocyte counts in metastatic PC.

Methods

Retrospective review of 178 metastatic pancreatic cancer patients. Associations between overall survival (OS), time to progression (TTP), chemotherapy schedule and SIRI at diagnosis were analyzed.

Results

Median age 67 years, 52% were male. First line chemotherapy regimens: 41% Gemcitabine, 31% Gemcitabine plus Nab-Paclitaxel and 17% mFOLFIRINOX. Patients with SIRI<2.3x109 showed a statistically significant improvement in OS compared to SIRI≥2.3x109 [16 months versus 4.8 months, Hazard Ratio (HR) 2.87, Confidence Interval (CI) 95% 2.02-4.07, p < 0.0001] that was confirmed in multivariate analysis. In addition, patients with SIRI<2.3x109 showed a longer TTP (12 versus 6 months, HR 1.92, IC 95% 1.314-2.800, P = 0.001). Furthermore, we observed that patients with SIRI ≥2.3x109 are more likely to benefit from mFOLFIRINOX therapy. Patients with an elevated SIRI treated with mFOLFIRINOX versus Gemcitabine plus Nab-Paclitaxel and Gemcitabine showed a clinically and statistically significant difference in median OS of 17 months compared to 6 and 4 months respectively (p < 0.001). Conversely, the difference was not clinically significant in the SIRI<2.3x109 subgroup: 15.9 months versus 16.5 and 16, respectively.

Conclusions

An elevated SIRI (≥2.3x109) is an independent prognostic factor for survival in patients with metastatic pancreatic cancer. Patients with an elevated SIRI (≥2.3x109) show an increased benefit from mFOLFIRINOX in comparison to other first line chemotherapy regimens. These results raise the issue of appropriately selecting patients who would benefit of a more intensive first-line chemotherapy regimen.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings